62 results - (0.000 seconds)

immune response:

    Sarah Varney August 10, 2020 12:07AM (UTC) This article originally appeared on Kaiser Health News. For a world crippled by the coronavirus, salvation hinges on a vaccine. But in the United States, where at least 4.6 million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded COVID-19: obesity. : Scientists know that vaccines engineered to protect the public from influenza, hepatitis B, tetanus and rabies can be less effective in obese adults than in the general population, leaving them more vulnerable to infection and illness. There is little reason to believe, obesity researchers say, that COVID-19 vaccines will be any different. "Will we have a...
    A third U.S. company has released results from a study indicating that its potential coronavirus vaccine is safe and sparks an immune response. Novavax Inc. released results from Phase 1 of its study showing that two doses of its COVID-19 vaccine candidate, NVX-CoV2373, elicited an immune response in 100% of the study's participants. The volunteers developed neutralizing antibodies at levels four times higher on average than antibodies developed by people who had contracted the coronavirus and recovered, according to the results. Cartoons on the CoronavirusView All 339 ImagesNeutralizing antibodies are antibodies that fight off the virus that causes COVID-19. The vaccine was given to participants with and without an adjuvant, a component to boost the immune system. The doses...
    (CNN)A third US company has released study results showing its coronavirus vaccine is safe and elicits an immune response. Novavax, Inc. released Phase 1 data Tuesday from 131 volunteers showing that after two doses of the vaccine, participants developed neutralizing antibodies at levels more than four times higher on average than the antibodies developed by people who had recovered from Covid-19. Neutralizing antibodies fight off the virus that causes Covid-19."That's good. That's really encouraging," said Novavax president Dr. Gregory Glenn. The vaccine also induced a response from T-cells, a type of immune cell, according to an analysis of 16 randomly selected volunteers, the report stated. The report has been submitted to a medical journal, but has not yet been reviewed...
    Dr. Sonia Macieiewski (R) and Dr. Nita Patel, Director of Antibody discovery and Vaccine development, look at a sample of a respiratory virus at Novavax labs in Rockville, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.Andrew Caballero-Reynolds | AFP | Getty Images Novavax's potential vaccine to prevent Covid-19 generated a promising immune response in an early-stage clinical trial, the U.S.-based biotech firm announced Tuesday. The phase one trial included 131 healthy participants between ages 18 and 59 at two sites in Australia. Novavax said 106 participants received the potential vaccine, named NVX-CoV2373, with or without an adjuvant, which is an ingredient designed to enhance the immune response. The remaining 25 patients received...
    Even as others were dying of COVID-19, Rick Wright made phone calls to his business clients. He lifted weights, did pushups and glided on an elliptical trainer. Late at night, he took his dog on long walks. “I never felt sick. Not a cough, wheezing, headache. Absolutely nothing,“ said 63-year-old Wright of Redwood City, despite testing positive for the virus – 40 days, straight — after being exposed aboard the Diamond Princess cruise last February. Seven months into a pandemic that has killed more than 667,000 people globally, scientists are searching for clues into why infected people like Wright feel just fine. Understanding the mystery of their protection may help suggest targets for vaccines and treatment. These cases also underscore...
    THE coronavirus vaccine could give immunity for at least 12 months, the chief behind British firm AstraZeneca's trial revealed. Sir Mene Pangalos, running the lab effort alongside Oxford University, said it could even give two years of protection from the killer bug, in a "big step forward". ⚠️ Read our coronavirus live blog for the latest news & updates 2The company is pushing to get the vaccines approved by OctoberCredit: Getty Images - Getty The head of BioPharmaceuticals Research and Development told BBC Newscast: "Based on precedent, with other studies that the Oxford Group have run, we’re hoping that the immune response will last for at least 12 months but hopefully closer to 24 or longer.” “You get your flu shot...
    As the world waits eagerly for a Covid-19 vaccine, several candidates are starting to be put through their paces in clinical trials. More than 100 vaccine candidates are being developed by teams around the world, with more than 20 now in or about to enter clinical evaluation, meaning they are being tested in humans.WIRED UKThis story originally appeared on WIRED UK. “When the world got the virus [RNA] sequence through on January 11, we knew pretty well immediately what kind of vaccine one would need and what bit of virus you would need to put in it, so the world of immunology was in a very good state to get going on that,” says Danny Altmann, a professor of immunology...
    Hope were rising last night that an arthritis drug could prove to be a breakthrough treatment for coronavirus. Doctors say anti-inflammatory treatment tocilizumab could save lives by halting the immune system ‘storm’ that has killed thousands of virus patients. Results of a major global trial are expected this week. Doctors say anti-inflammatory treatment tocilizumab could save lives by halting the immune system ‘storm’ that has killed thousands of virus patients (file photo) Doctors are confident the drug, which was originally developed as a treatment for rheumatoid arthritis, will stop the hyper-inflammation that happens when the immune system starts attacking the body.  It could dramatically reduce coronavirus deaths – many of which are caused by the aggressive immune response rather...
    The key tool to relax containment measures and return to a state as close to normal as possible is a covid-19 vaccine. How far have those efforts gone? Which vaccines have advanced the most in their development process? And when will they be available to immunize the population and protect it from SARS-CoV-2? BBC Mundo reviews the most important advances. Presentational gray line shorts More Before looking at each one in more detail, let’s briefly recall what path a vaccine takes until it is approved. This means that, although a vaccine against covid-19 shows great promise in terms of safety and the immune response it generates in the early stages, it cannot be known whether it will help prevent...
    Hopes for a coronavirus vaccine before Christmas have been dashed by a World Health Organization expert.  Mike Ryan, head of WHO's emergencies programme, said the first use of a Covid-19 vaccine cannot be expected until early 2021.  He noted that several vaccines are now in phase three trials and none have failed so far in terms of safety or ability to generate an immune response.   His comments come after Oxford University — one of the frontrunners in a race for a vaccine —  claimed there was still a chance it could deliver its experimental jab by Christmas if tests keep going according to plan.    One of the researchers working on the project had said that people in the most at-risk groups could get...
    There are over 300,000 viruses that infect mammals, but there are only seven coronaviruses that infect humans. Four of these, known by the less-than-alternative labels 229E, NL63, OC43, and HKU1 produce generally mild illnesses and are responsible for about 15% of what people refer to as the “common cold.” Exposure to these viruses generates a mild and rapidly falling immune response, meaning that people can be infected again by the same coronavirus in a matter of a few months. Of the remaining human coronaviruses, two are SARS-CoV and MERS-COV, which generate extremely serious illness with a high rate of fatalities. And then there is SARS-CoV-2, the virus behind the disease COVID-19. From the beginning, there have been worries that this virus might combine the worst of...
    A senior British official has called the latest news on an Oxford University team's potential coronavirus vaccine "extremely encouraging." The results of the Phase I/II trial of the vaccine being developed by Oxford's Jenner Institute, in conjunction with pharmaceutical giant AstraZeneca, showed that it is safe and "produced strong immune results," according to the research published on Monday in The Lancet medical journal. The vaccine caused a 2-pronged immune response, a news release from the Jenner Institute at Oxford said. First, within 14 days, it triggered a T cell response, generating white blood cells that can attack infected cells. Second, within 28 days, it provoked an antibody response. Antibodies are able to prevent the virus from infecting cells when it...
    CHICAGO (WLS) -- There is some good news in the race for a COVID-19 vaccine as trials involving three different vaccines all showed positive results Monday.But a local researcher is among those concerned that no vaccine trial takes sex into consideration.RELATED: COVID-19 vaccine hopes rise after strong trial results in England Nicole Woitowich, associate director of the Northwestern University's Women's Health Research Institute, says the differences between men and women go beyond the obvious."Women on average are able to mount a greater immune response to vaccines and have more of a protective immune response against viruses and other infection compared to men," Woitowich said.She said as researchers race to find a COVID-19 vaccine, sex should be part of the studies...
    (CNN) — Results from trials involving three different coronavirus vaccines released Monday, all showed positive results, with evidence the vaccines can produce immune responses that would be expected to protect people against infection. They all also appeared to be safe, although it will take studies with more people to show how safe they really are and whether they can prevent infection. Early results of a closely watched Phase 1/2 trial published in The Lancet suggest a coronavirus vaccine developed by the University of Oxford and AstraZeneca is safe and induces an immune response. However, researchers stressed more study is needed to know whether the vaccine protects people against the virus. Phase 2 results for one vaccine candidate made by Chinese company CanSino...
    LONDON (CBSMiami) – COVID-19 continues its stronghold in the state of Florida but there could be some good news on a potential vaccine. New preliminary research is encouraging on two coronavirus vaccines being developed outside the United States. Researchers are having promising results with an experimental vaccine being developed by the University of Oxford and the pharmaceutical company AstraZeneca. The study in The Lancet looked at more than 1,000 healthy adults and found the vaccine induced strong antibody and immune responses. “What this vaccine does particularly well is trigger both arms of the immune system, so in addition to neutralizing antibodies, which other vaccines do, we also see a very strong t-cell response,” explained Professor Adrian Hill, director of the...
    Ed CaraJust now•Filed to:covid-19covid-19coronavirusvaccinesscienceSARS-CoV-2SaveA sign outside the AstraZeneca factory in Liverpool, England. The company has pledged to mass-produce and sell doses of the vaccine developed by researchers from Oxford University, should it prove effective in preventing covid-19. Photo: Paul Ellis (Getty Images) A study from the UK is the latest to provide some early hope for an effective vaccine against the coronavirus that causes covid-19. Earlier today, Oxford University researchers revealed the promising results from an early phase clinical trial of their vaccine candidate. The vaccine appeared to be safely tolerated in healthy people; it also seemed to create a robust immune response in volunteers, though it’s still too soon to know whether that response will result in protective immunity....
    By Julie Steenhuysen CHICAGO (Reuters) - Early data from trials of three potential coronavirus vaccines released on Monday, including a closely-watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight COVID-19 without serious side effects. Whether any of these efforts will result in a safe and effective vaccine capable of protecting billions of people and ending the global pandemic is still far from clear. All will require much larger studies to prove they can prevent infection with the virus. The vaccine being developed by British drugmaker AstraZeneca along with Oxford University, induced an immune response in all study participants who received two doses without any worrisome side effects. A coronavirus vaccine...
    (CNN)Results from trials involving three different coronavirus vaccines released Monday, all showing positive results, with evidence the vaccines can produce immune responses that would be expected to protect people against infection.They all also appeared to be safe, although it will take studies with more people to show how safe they really are and whether they can prevent infection.Early results of a closely watched Phase 1/2 trial published in The Lancet suggest a coronavirus vaccine developed by the University of Oxford and AstraZeneca is safe and induces an immune response. However, researchers stressed more study is needed to know whether the vaccine protects people against the virus.Phase 2 results for one vaccine candidate made by Chinese company CanSino Biologics were also...
    Food and Drug Administration Commissioner Stephen Hahn is “cautiously optimistic” about a safe and effective coronavirus vaccine after promising results on a potential vaccine were published, he told “America’s Newsroom” on Monday. The early results of Oxford University and AstraZeneca’s coronavirus vaccine trial showed “robust” immune system responses, according to the pharmaceutical firm. In the research, scientists said that they found their experimental COVID-19 vaccine, AZD1222, produced a dual immune response in people aged 18 to 55. Dr. Adrian Hill, director of the Jenner Institute at Oxford University, said neutralizing antibodies were produced by the vaccine candidate. In addition, the vaccine also causes a reaction in the body's T-cells, which help to fight off the coronavirus. “We are seeing good immune response in almost everybody,” said Hill....
    LONDON, England -- Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot.British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case, experts were also looking to see what kind of immune response was provoked.In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.SEE RELATED STORY: When there's a coronavirus vaccine, who will get it first?"We are seeing...
    Oxford University scientists said that early vaccine test results showed protective immune responses, the first step in evaluating the safety and effectiveness of the vaccine, per the Associated Press. “I think it’s going to be very difficult to control this pandemic without a vaccine,” Dr. Adrian Hill, director of the Jenner Institute at Oxford University, told the AP. Hill added that while the vaccine tests performed well, he is still concerned infections are outpacing vaccine production. (RELATED: Young People Are Allegedly Creating Mask-Free Coronavirus Speakeasies As Infection Rate Among That Generation Rises) Hill told the AP that the vaccine triggers “both arms of the immune system” by producing neutralizing antibodies to block infection and creating T-cells to destroy cells taken...
    Getty A glass sculpture entitled "coronavirus COVID-19" created by British artist Luke Jerram is seen at his studio in Bristol, southwest of England on March 17, 2020. Oxford University’s pursuit of a viable COVID-19 vaccine continues to show promising results, as researchers discovered the vaccine they’re working on works to boosts antibodies that neutralize the virus, making it unable to infect human cells, according to the University of Oxford. The results of the ongoing study were published Monday in the journal, Lancet. Oxford scientists have been working on the vaccine since January and in April they started human trials. What they’ve found so far is, “100% of participants’ blood having neutralizing activity against the coronavirus. The next...
    Oxford University COVID-19 Vaccine Prompts Immune Response In Early Test
    A potential coronavirus vaccine being developed in the U.K. prompted a strong immune response in an early trial, according to new research. [ SEE: The Latest News on the Coronavirus Outbreak ]Experts from Oxford University detailed their findings in a study published Monday in the medical journal The Lancet. While the study authors cautioned that more research needs to be done, the vaccine produced an immune response in healthy people aged 18 to 55. "The immune responses observed following vaccination are in line with what previous animal studies have shown are associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial programme to confirm this in humans," professor Andrew Pollard, chief investigator of the Oxford Vaccine...
    LONDON — Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are designed to evaluate safety and see what kind of immune response was provoked, but can’t tell if the vaccine truly protects. In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized. “We are seeing good...
    The early results of Oxford University and AstraZeneca’s coronavirus vaccine trial showed “robust” immune system responses, according to the pharmaceutical firm. “COVID-19 vaccine AZD1222 showed robust immune responses in all participants in phase I/II trial,” said AstraZeneca in an emailed statement. Some 1,077 people took part in the study of AZD1222, which is also known as ChAdOx1 nCoV-19. About half of the participants received the experimental vaccine. UK CORONAVIRUS VACCINE TRIAL IS 'PROGRESSING VERY WELL,' RECRUITING CHILDREN AND OLDER ADULTS In the research, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55. Dr. Adrian Hill, director of the Jenner Institute at Oxford University, said neutralizing antibodies were produced by the vaccine...
    Oxford University scientists have claimed that an early trial of a potential coronavirus vaccine has prompted an immune response in hundreds of people. “We are seeing good immune response in almost everybody,” Dr. Adrian Hill, director of the Jenner Institute at Oxford University, told London AP. “What this vaccine does particularly well is trigger both arms of the immune system.” The dual immune response in those years 18-55 lasted at least two months after the experimental vaccine was distributed, according to research published in the Lancet journal. The initial trial included testing the potential vaccine on 1,000 people, and later experiments will involve 10,000 people, while one in the U.S. will test on 30,000. “There’s increasing evidence that having...
    By MARIA CHENG | The Associated Press LONDON — Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case experts were also looking to see what kind of immune response was provoked. In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months...
    Laboratory to conduct research on the coronavirus (COVID-19) in order to diagnose, test and develop a vaccine. (Photo by Pedro Vilela/Getty Images) LONDON (AP) — Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case experts were also looking to see what kind of immune response was provoked. In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine...
    By MARIA CHENG, AP Medical Writer LONDON (AP) — Scientists at Oxford University say their experimental coronavirus vaccine has been shown in an early trial to prompt a protective immune response in hundreds of people who got the shot. British researchers first began testing the vaccine in April in about 1,000 people, half of whom got the experimental vaccine. Such early trials are usually designed only to evaluate safety, but in this case experts were also looking to see what kind of immune response was provoked. In research published Monday in the journal Lancet, scientists said that they found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months...
    A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020.Dado Ruvic | Reuters A potential coronavirus vaccine developed by Oxford University in the U.K. has produced a strong immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet. Oxford researchers, in partnership with pharmaceutical giant AstraZeneca, are calling their experimental vaccine ChAdOx1 nCoV-19. It combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees. The phase one trial had more than 1,000 participants. Professor Adrian Hill, director of Oxford University's Jenner Institute, told CNBC on Monday that the strong...
    LONDON (AP) — Researchers: In early testing, UK coronavirus vaccine prompts immune response. Copyright © 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
    (CBS DETROIT) – Volunteers apart of the first Covid-19 vaccine tested in the U.S. showed signs of an immune response according to researchers. The experimental vaccine was developed by Moderna and the National Institutes of Health. In the New England Journal of Medicine the team reported that the 45 people who received the vaccine, now have neutralizing antibodies which is key to blocking infection. Dr. Anthony Fauci also says just because a vaccine may be available in January, doesn’t mean the problem will be completely over with. © 2020 CBS Broadcasting Inc. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. Related
    Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City BY KATE KELLAND Early-stage human trial data on a vaccine being developed by AstraZeneca and Oxford University will be published on July 20, The Lancet medical journal said on Wednesday. The vaccine candidate is already in large-scale Phase III human trials to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results which would show whether it is safe and whether or not it induces an immune response. “We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20, for immediate release,” a spokeswoman for the journal...
    HOPES of a successful coronavirus vaccine have been boosted after volunteers showed signs of immunity in separate trials. Two experimental projects - one in the UK and the other in the US - have now reportedly shown promise in the fight against Covid-19. ⚠️ Read our coronavirus live blog for the latest news & updates 4Hopes of a coronavirus vaccine have been boosted after volunteers showed signs of immunity in two separate trialsCredit: Reuters The British team, from Oxford University, is understood to be focusing on T-cells - which develop as a result of a long-lasting immune response. They have previously said they are "80 per cent" confident they will have a working jab by September. Meanwhile, a potential coronavirus...
    MOSCOW (Reuters) - Russian scientists hailed the results of their first clinical trial of a potential coronavirus vaccine on Wednesday, saying it had been proved safe and that volunteers had developed an immune response. Speaking to a crowded room without wearing masks, three of 18 volunteers monitored over a month at the Sechenov University said they all had experienced few side-effects. A larger-scale trial, intended to ascertain the strength of the immune response produced by the vaccine and how long protection will last, is expected to begin in Russia in mid-August. More than 100 possible vaccines are being developed and tested around the world to try to stop the pandemic. Of 19 in human trials, only two are in the...
    (CNN)A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.These early results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects -- fatigue, chills, headache, muscle pain, pain at the injection site -- becoming the first US vaccine candidate to publish results in a peer-reviewed medical journal The vaccine is expected to begin later this month a large Phase 3 trial -- the final trial stage before regulators consider whether to make the vaccine available. Early results from...
    The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study volunteers who were given either a low or medium dose.Ted S. Warren | AP Moderna's potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, providing more promising data that the vaccine may give some protection against the coronavirus, according to newly released data published Tuesday evening in the peer-reviewed New England Journal of Medicine. All 45 patients produced neutralizing antibodies, which scientists believe are important for gaining protection against the virus. In the trial, each participant received a 25, 100 or 250 microgram dose, with 15...
    By Kate Kelland LONDON (Reuters) - Emerging evidence that the body's immune defence against COVID-19 may be short-lived makes it even harder for vaccine developers to come up with shots fully able to protect people in future waves of infection, scientists said on Tuesday. Preliminary studies in China, Germany, Britain and elsewhere have found that patients infected with the novel coronavirus make protective antibodies as part of their immune system's defences, but these appear to last only a few months. "Most people make them (antibodies), but often they can wane rather rapidly, suggesting there could be little immunity," said Daniel Altmann, a professor of immunology at Imperial College London. That raises big problems for developers of potential COVID-19 vaccines, experts...
    Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City BY KATE KELLAND Emerging evidence that the body’s immune defense against COVID-19 may be short-lived makes it even harder for vaccine developers to come up with shots fully able to protect people in future waves of infection, scientists said on Tuesday. Preliminary studies in China, Germany, Britain and elsewhere have found that patients infected with the novel coronavirus make protective antibodies as part of their immune system’s defenses, but these appear to last only a few months. “Most people make them (antibodies), but often they can wane rather rapidly, suggesting there could be little immunity,” said Daniel Altmann, a professor of...
    Another scientific study has confirmed that 5G is 'harmless and benign' in response to crackpot conspiracy theorists who say the next-gen network causes disease. US researchers investigating the effects of radio-frequency radiation generated by the ultra-fast mobile internet reveal that it has negligible health impacts.   The study comes after several 5G masts were vandalised during the coronavirus lockdown following unfounded conspiracy theories saying the form of wireless communication causes Covid-19. Theorists have claimed the fifth-generation wireless standard, which began widespread deployment last year, emits radiation that lowers the immune system. Despite providing essential communications technology during the pandemic, 5G masts have been subject to arson attacks throughout the UK.  Scroll down for video  Findings from an Oregon State University...
    If you want to know if you’ve ever been infected with SARS-CoV-2, the natural thing to do is to get a blood test. These look for antibodies—proteins that signal your body has encountered a virus, and could perhaps be protected from catching it again. But recently, a study published in Nature Medicine introduced a worrying complication. Researchers in Chongqing, China, followed 37 people who had tested positive for the virus but didn’t show symptoms during their illness—in other words, who were asymptomatic—and tested their blood regularly. They found those antibodies didn’t always last for long: In some cases, after two to three months, they were barely detectable. Thought a positive antibody test was your ticket out of this thing? It’s...
    By Deena Beasley (Reuters) - As scientists question whether the presence, or absence, of antibodies to the novel coronavirus can reliably determine immunity, some are looking to a different component of the immune system, known as T cells, for their role in protecting people in the pandemic. Recent studies show that some recovered patients who tested negative for coronavirus antibodies did develop T cells in response to their COVID-19 infection. While the studies are small and have yet to be reviewed by outside experts, some scientists now say that people who experience a mild illness, or no symptoms at all, from the new coronavirus, may be eliminating the infection through this T cell response. The findings add to the evidence...
    (CNN)This has been a rough week in the middle of a rough year.After so many of us made serious sacrifices to stem the spread of the coronavirus, we let our guard down. What little leadership and communication we got from the White House in the early days of the pandemic have disappeared, and the tremendous gains the country made against the contagion after several weeks of lockdown have all but vanished. The US is now seeing a surge in new infections -- with highs exceeding more than 55,000 new cases in a day last week -- and hospital beds in certain hotspots are approaching capacity.Erin Bromage New York, New Jersey and Massachusetts fought hard-won battles in April and May, and...
    Today, like every day, Eric Verdin will cycle the steep hills of Marin County. He’ll wait until noon to eat his first meal. He’ll wear a mask and stay socially distanced. He’ll be asleep no later than 11 p.m. Despite his excellent health, the 63-year-old scientist and CEO of the Buck Institute for Research on Aging knows he must do everything he can to protect himself from this hard truth: As we age, our body’s elegant symphony of immune cells turns dissonant. We may feel fine. But our hidden defenses no longer fully shield us – and may turn against us. As COVID-19’s case count explodes, “This is the time more than ever to adopt the healthiest lifestyle that you...
    A coronavirus vaccine spearheaded by Pfizer and BioNTech bolstered immune response to the virus in some, but in others — especially in large doses — the experimental drug caused fevers and other side effects, according to a study Pfizer released Wednesday. Researchers reported “moderate increases” in immune response to the COVID-19 pathogen in those that received low and medium doses of the vaccine. The serum was administered in two doses and “substantially greater” results were observed after a second dose, according to the study, which has not been peer reviewed yet. Those who received the treatment gained double, and at most nearly triple, the coronavirus antibodies of those who recovered from the virus naturally, according to the study. But the experimental serum...
    A steroid found to help severely ill coronavirus patients does nothing to help people with milder cases, a new study suggests. Last week, British researchers published preliminary findings showing that  dexamethasone reduced death rates among patients on ventilators and those on supplemental oxygen without ventilation. But, in the full report released this week, results showed that patients not receiving any type of oxygen support fared better when receiving usual care rather than the drug. Since the early findings were first announced, demand for dexamethasone has surged by 610 percent, in some cases outstripping supply of the medication.  Last week, UK researchers revealed that dexamethasone, a steroid, reduced death rates by one-fifth in those receiving supplemental oxygen (left) and by...
    The Pirbright Institute, working in collaboration with the University of Oxford, announced on Tuesday that two doses of an experimental COVID-19 vaccine successfully produced a greater antibody response than a single dose in pigs. The Surrey, England institute released research showing that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine revealed a “marked increase of neutralising antibodies,” which bind to the virus to block infection. CLICK HERE FOR FULL CORONAVIRUS COVERAGE The same investigational vaccine previously protected six monkeys from pneumonia caused by the virus. The ChAdOx1 nCoV-19 vaccine is made from the ChAdOx1 virus, a weakened version of the common cold that has been genetically changed so that it is impossible for it to replicate in humans, according to the Oxford researchers....
    Coronavirus — The different characteristics of our immune response according to age suggest that we should opt for several vaccines against SARS-CoV-2 instead of only one. The immune response against viruses consists of a series of cascading events that escalate if the organism is not able to control the infection quickly. First, the innate immune system is mobilized, whose majority representatives are the macrophages, which develop the same type of response regardless of the infectious agent. If it is not enough to kill the pathogen, the adaptive or acquired immune system is mobilized, much more sophisticated and dependent on the type of bacteria or virus. The protagonists of the adaptive immune response are the lymphocytes, capable of generating antibodies...
    Coronavirus — The study was applied in 300 covid-19 patients and their contacts, which allowed identifying viral proteins to design the antigen; the next step is preclinical testing on mice Regeneration, June 20, 2020. The Mexican Institute of Social Security (IMSS) develops a protein-based vaccine from SARS CoV-2 coronavirus, from the study of the antibodies produced by its first 300 patients covid-19 and through the use of an immune response enhancer already patented by the institution. The above was made known in an exclusive interview for Millennium by Constantino López Macías, head of the Medical and Immunochemical Research Unit (UIMIQ) of the High Specialty Medical Unit (UMAE) Specialty Hospital of the XXI Century National Medical Center. “To know how...
    Asymptomatic coronavirus patients have a weaker immune response to the virus, according to a China study. The findings of the study, which has not been throgh a rigorous peer review process, were published on the pre-print website medRxiv. Scientists examined the blood samples of 1,470 COVID-19 patients in three hospitals in Wuhan, China, the first epicenter of the pandemic, to determine if they had antibodies for the virus. They also assessed the blood of 3,832 health care providers who did not test positive for the coronavirus from three hospitals in Wuhan. VideoThe team found that 89 percent of hospitalized COVID-19 patients had virus-specific antibodies against the coronavirus, compared with 4 percent of health care workers and the general population, and...